Compounds > celecoxib

celecoxib and sirolimus

celecoxib has been researched along with sirolimus in 19 studies

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (10.53)29.6817
2010's13 (68.42)24.3611
2020's4 (21.05)2.80

Authors

AuthorsStudies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Kmoníčková, E; Peterková, L; Rimpelová, S; Ruml, T1
Becker, B; Bundscherer, A; Hafner, C; Landthaler, M; Maisch, T; Vogt, T1
Oberyszyn, TM; Schick, JS; Thomas-Ahner, JM; Wulff, BC1
Bundscherer, A; Hafner, C; Köhl, G; Landthaler, M; Vogt, T1
Edelman, M; Gendy, AS; Glick, RD; Lipskar, A; Soffer, SZ; Steinberg, BM1
Bartos, A; Bradshaw, H; Cha, J; Dey, SK; Egashira, M; Haraguchi, H; Hirota, Y; Leishman, E; Saito-Fujita, T1
Chang, HC; Chang, SC; Chiang, CK; Chou, CT; Chuang, YT; Ho, IL; Hsu, CH; Huang, KH; Kuo, KL; Lee, PY; Lin, WC; Liu, SH; Pu, YS1
Hao, H; Li, J; Li, R; Luo, J; Xue, L1
Cappelletti, M; Daikoku, T; Dey, SK; Ellenson, LH; Hossain, MM; Terakawa, J; Yang, P; Yoshie, M1
Cao, Y; Hou, K; Li, C; Liu, Y; Qu, J; Qu, X; Yang, D; Zheng, H1
Chen, X; Hu, Z; Ji, S; Jiang, K; Jin, F; Li, H; Liu, Y; Ni, Z; Qin, Y; Wang, L; Zha, X; Zhang, H1
Bastiaansen-Jenniskens, YM; Bayon, Y; Boersema, GSA; Lange, JF; Utomo, L; van Osch, GJVM1
He, XX; Li, PY; Liao, JZ; Liu, C; Liu, L; Sheng, JQ; Tian, DA; Wu, XL; Zhu, HD1
Cash, T; Goldsmith, KC; Katzenstein, HM; Kean, L; MacDonald, TJ; Qayed, M; Suessmuth, Y; Tanos, R; Tighiouart, M; Watkins, B; Wetmore, C1
Bartlett, DL; Guo, ZS; Liu, J; McFadden, G; Roy, EJ; Schane, CP; Shisler, JL; Tang, B; Thomas, DL; Yan, DZ1
Burke, CA; Chick, RC; Cindass, JL; Clifton, GT; Ensley, DC; Hale, DF; Hickerson, AT; Kemp Bohan, PM; Mankaney, G; Peoples, GE; Sohn, V; Vreeland, TJ1

Reviews

3 review(s) available for celecoxib and sirolimus

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.
    Journal of medicinal chemistry, 2020, 03-12, Volume: 63, Issue:5

    Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Gene Regulatory Networks; Humans; Neoplasms; Protein Structure, Secondary; Sarcoplasmic Reticulum Calcium-Transporting ATPases

2020
Chemoprevention in familial adenomatous polyposis: past, present and future.
    Familial cancer, 2021, Volume: 20, Issue:1

    Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Ascorbic Acid; Aspirin; Capsules; Celecoxib; Chemoprevention; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Eflornithine; Erlotinib Hydrochloride; Fatty Acids, Nonesterified; Genes, APC; Humans; Sirolimus; Sulindac; TOR Serine-Threonine Kinases; Vitamins

2021

Trials

1 trial(s) available for celecoxib and sirolimus

ArticleYear
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:4

    Topics: Administration, Metronomic; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Sirolimus; Young Adult

2020

Other Studies

15 other study(ies) available for celecoxib and sirolimus

ArticleYear
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines.
    Oncology reports, 2008, Volume: 19, Issue:2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Melanoma; Pyrazoles; RNA, Messenger; Sirolimus; Skin Neoplasms; Sulfonamides

2008
Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs.
    International journal of cancer, 2010, Jan-01, Volume: 126, Issue:1

    Topics: Animals; Blotting, Western; Caspase 3; Celecoxib; Cyclooxygenase Inhibitors; Cyclosporine; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Female; Immunohistochemistry; Immunosuppressive Agents; Mice; Neoplasms, Radiation-Induced; Pyrazoles; Sirolimus; Skin Neoplasms; Sulfonamides; Tumor Suppressor Protein p53; Ultraviolet Rays

2010
Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines.
    Anticancer research, 2010, Volume: 30, Issue:10

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Growth Processes; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Hemangiosarcoma; Humans; Mice; Pyrazoles; Sirolimus; Sulfonamides

2010
Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma.
    Journal of pediatric surgery, 2011, Volume: 46, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Female; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrazoles; Sarcoma, Ewing; Sirolimus; Sulfonamides

2011
Combinatory approaches prevent preterm birth profoundly exacerbated by gene-environment interactions.
    The Journal of clinical investigation, 2013, Volume: 123, Issue:9

    Topics: 20-Hydroxysteroid Dehydrogenases; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Decidua; Drug Therapy, Combination; Female; Gene Expression; Gene-Environment Interaction; Glycoproteins; Intercellular Signaling Peptides and Proteins; Lipopolysaccharides; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Transgenic; Multiprotein Complexes; Ovary; Pregnancy; Premature Birth; Progesterone; Pyrazoles; Receptors, Prolactin; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53

2013
Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells.
    PloS one, 2013, Volume: 8, Issue:12

    Topics: Adenine; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Carcinoma, Transitional Cell; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Macrolides; MAP Kinase Kinase 4; Phosphoproteins; Pyrazoles; RNA, Small Interfering; Signal Transduction; Sirolimus; Sulfonamides; Ubiquitin-Activating Enzymes; Urinary Bladder Neoplasms

2013
Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Pyrazoles; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases

2014
Mammalian target of rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer.
    The American journal of pathology, 2014, Volume: 184, Issue:9

    Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Endometrial Neoplasms; Female; Humans; Immunohistochemistry; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Multiprotein Complexes; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases

2014
Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:7

    Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Pyrazoles; Signal Transduction; Sirolimus; Stomach Neoplasms; Sulfonamides; TOR Serine-Threonine Kinases

2015
mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
    Oncotarget, 2016, May-10, Volume: 7, Issue:19

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Down-Regulation; Mechanistic Target of Rapamycin Complex 1; Mice; Neoplasms; Rats; Sirolimus; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins

2016
In vitro modulation of the behavior of adhering macrophages by medications is biomaterial-dependent.
    Biomedical materials (Bristol, England), 2017, 03-07, Volume: 12, Issue:2

    Topics: Biocompatible Materials; Celecoxib; Cell Adhesion; Cells, Cultured; Chemokines, CC; Dexamethasone; Gene Expression; Humans; Inflammation Mediators; Interleukin-6; Macrophage Activation; Macrophages; Materials Testing; Monocytes; Phenotype; Polyesters; Polyethylene Terephthalates; Polypropylenes; Pravastatin; Sirolimus

2017
Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux.
    Scientific reports, 2018, 03-07, Volume: 8, Issue:1

    Topics: Animals; Autophagy; Celecoxib; Cell Line; Chloroquine; Diet, High-Fat; Humans; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Sirolimus

2018
Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 05-01, Volume: 26, Issue:9

    Topics: Animals; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Synergism; Female; Glioma; Immunosuppressive Agents; Immunotherapy; Immunotherapy, Adoptive; Interleukin-15; Male; Mice, Inbred C57BL; Myxoma virus; Oncolytic Virotherapy; Receptors, Interleukin-15; Sirolimus; Vaccinia virus

2020